Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Current Assets (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Current Assets for 11 consecutive years, with $527.7 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 17.53% to $527.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $527.7 million through Dec 2025, down 17.53% year-over-year, with the annual reading at $527.7 million for FY2025, 17.53% down from the prior year.
  • Current Assets for Q4 2025 was $527.7 million at Intellia Therapeutics, down from $581.9 million in the prior quarter.
  • The five-year high for Current Assets was $1.2 billion in Q4 2022, with the low at $495.9 million in Q2 2025.
  • Average Current Assets over 5 years is $776.3 million, with a median of $792.0 million recorded in 2021.
  • The sharpest move saw Current Assets skyrocketed 122.82% in 2021, then tumbled 37.63% in 2025.
  • Over 5 years, Current Assets stood at $769.3 million in 2021, then skyrocketed by 58.17% to $1.2 billion in 2022, then decreased by 17.95% to $998.3 million in 2023, then crashed by 35.91% to $639.9 million in 2024, then fell by 17.53% to $527.7 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $527.7 million, $581.9 million, and $495.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.